GET DAILY SIGNALSJohnson & Johnson (JNJ) Q2 2026 Earnings Preview: What Analysts Are Watching
Key Takeaways
- Analysts expect Q2 2026 adjusted EPS of approximately $2.85, up from $2.70 in Q1 2026.
- Consensus revenue estimate stands near $25.18 billion, reflecting modest year-over-year growth.
- Investors will focus on performance across Innovative Medicine and MedTech segments.
- Company raised full-year 2026 guidance following strong Q1 results.
- Historical stock reactions to earnings have varied based on beats or misses relative to estimates.
- Broader healthcare sector trends and macroeconomic factors may influence sentiment.
Putting the Upcoming Report in Context
Johnson & Johnson reports results on a calendar-year basis, with the second quarter covering April through June. The upcoming report follows a solid Q1 2026 performance in which the company reported adjusted EPS of $2.70 and revenue of $24.06 billion while raising its full-year outlook. Earnings releases provide critical updates on pharmaceutical sales, medical device demand, and overall profitability, helping investors assess the company’s ability to navigate competitive pressures and regulatory environments in healthcare.
Consensus Estimates and Key Metrics
Wall Street consensus points to Q2 2026 adjusted EPS of about $2.85 and revenue near $25.18 billion. These figures represent modest growth compared with the prior-year quarter. Analysts will also monitor any updates to the company’s full-year 2026 guidance, which was increased after Q1 results to reflect estimated reported sales of $100.8 billion at the midpoint. Key metrics include segment revenues for Innovative Medicine and MedTech, adjusted operational growth rates, and commentary on pipeline progress or cost management. Historically, the stock has shown measured reactions to earnings that align closely with or modestly exceed expectations.
I also checked this using Tickeron’s AI Screener to see how JNJ compares to others in the industry.
Market Sentiment Heading Into the Report
Sentiment heading into the Q2 report remains cautiously optimistic following the company’s recent guidance raise. Investors are watching for confirmation of steady growth in core businesses amid a stable healthcare backdrop. Pre-earnings positioning often reflects expectations of in-line or slightly better results, with potential for volatility if outcomes deviate meaningfully from consensus. Sector peers and macroeconomic data releases around the same period can also shape broader market response.
What to Watch After the Numbers Drop
Following the earnings release, attention will shift to management commentary on full-year guidance and segment-specific trends. Investors should track updates on pharmaceutical product demand, including any contributions from recent launches or pipeline advancements. In MedTech, monitoring procedure volumes and competitive dynamics remains important. Cost discipline, margin trends, and any adjustments to operational forecasts will provide additional context for the balance of 2026.
Broader industry conditions, such as healthcare spending patterns and regulatory developments, could influence results. Currency fluctuations and supply chain factors may also warrant review in management remarks. These elements help frame expectations for subsequent quarters without relying on short-term price movements.
Enhancing Research with AI Tools
When preparing for earnings like this one, I find it helpful to supplement traditional analysis with modern screening capabilities. The AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener helps identify trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. I’ve used it to quickly compare JNJ against peers and spot relevant patterns ahead of reports like this. Explore the AI Screener to discover opportunities aligned with your strategy.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsContributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
JNJ in upward trend: 10-day moving average moved above 50-day moving average on October 30, 2026
The 10-day moving average for JNJ crossed bullishly above the 50-day moving average on October 30, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where JNJ's RSI Indicator exited the oversold zone, 17 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 59%.
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on JNJ as a result. In 38 of 84 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 45%.
The Moving Average Convergence Divergence (MACD) for JNJ just turned positive on October 21, 2026. Looking at past instances where JNJ's MACD turned positive, the stock continued to rise in 19 of 47 cases over the following month. The odds of a continued upward trend are 40%.
JNJ moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +2.41% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 163 of 354 cases, the price rose further within the following month. The odds of a continued upward trend are 46%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 32 of 62 cases where JNJ's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 52%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 43%.
JNJ broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for JNJ entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 2 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 7 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 19 (best 1 - 100 worst), indicating outstanding price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.834) is normal, around the industry mean (-1.421). P/E Ratio (31.640) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (2.852) is also within normal values, averaging (5.738). Dividend Yield (0.019) settles around the average of (0.038) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement